Yan X, et al. - Researchers retrospectively examined the clinical data of 76 subjects to assess the efficiency of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. They observed no meaningful difference in the response rate between the different groups. They observed that PFS and OS were significantly longer in the combination group than in the monotherapy group for individuals with the exon 21 L858R mutation. The frequency of adverse incidents was noted significantly higher in the combination group but all adverse reactions were expected and well tolerated.